The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease  The FDA approved aducanumab, also known as Aduhelm, using its "accelerated approval" program, which allows for the earlier approval of a drug for a serious or life-threatening illness even though more study into the drug's benefits may be needed. --- Send in a voice message: https://anchor.fm/awaregiver/message